Lavinia Reyes, MD
Internal Medicine · Raleigh, NCNPI 1467498840
Payments from drug & device makers
Across 323 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$596
- AstraZeneca$462
- Boehringer Ingelheim$370
- Pfizer$339
- GSK$256
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,975100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 79 | $1,136 |
| Lilly USA, LLC | 40 | $596 |
| AstraZeneca | 27 | $462 |
| Boehringer Ingelheim | 24 | $370 |
| Pfizer | 31 | $339 |
| GSK | 15 | $256 |
| Novartis | 16 | $238 |
| Abbott | 9 | $213 |
| Sanofi-aventis U.S. LLC | 12 | $194 |
| AbbVie(2 entities) | 7 | $135 |
| Exact Sciences | 6 | $133 |
| Bayer | 7 | $122 |
| Amgen | 8 | $110 |
| Astellas Pharma US Inc | 4 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Merck | 5 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Amarin Pharma, Inc. | 4 | $55 |
| Johnson & Johnson | 4 | $48 |
| Lundbeck LLC | 3 | $45 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Gilead | 2 | $30 |
| Si-bone, Inc. | 1 | $29 |
| Boston Scientific | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$4,984 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 306 | $424,822 |
| JardianceEmpagliflozin | 191 | $195,760 |
| EliquisApixaban | 226 | $189,811 |
| MounjaroTirzepatide | 103 | $120,985 |
| FarxigaDapagliflozin Propanediol | 95 | $85,075 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $78,972 |
| JanuviaSitagliptin Phosphate | 90 | $78,121 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $56,316 |
| TrulicityDulaglutide | 43 | $50,705 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $48,683 |
| Repatha SureclickEvolocumab | 61 | $48,263 |
| TradjentaLinagliptin | 46 | $35,128 |
| CreonLipase/Protease/Amylase | 12 | $31,041 |
| XareltoRivaroxaban | 11 | $17,844 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $16,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,136 | $424,822306 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $370 | $244,229254 claims |
| PfizerEliquis | $339 | $189,811226 claims |
| Lilly USA, LLCMounjaro, Trulicity | $596 | $171,689146 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $462 | $98,519118 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $256 | $95,111104 claims |
| MerckJanuvia, Janumet Xr | $71 | $87,373102 claims |
| AbbVieCreon, Synthroid | $135 | $39,321110 claims |
| Johnson & JohnsonXarelto | $48 | $17,84411 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $15,89839 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $4,734434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Raleigh
- John RubinoRaleigh$13M
- Wayne HarperRaleigh$6.7M
- Bhakti PaulRaleigh$536K
- Clifford CurtisRaleigh$376K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.